Arta Dreimane

Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia

Mette Ilander, Ulla Olsson‐Strömberg, Heinrich Schlums et al. · Leukemia · 2016 · 247 citations · Full text

Medicine, Hematology, Immunology +14

Tyrosine kinase inhibitor usage, treatment outcome, and prognostic scores in CML: report from the population-based Swedish CML registry

Martin Höglund, Fredrik Sandin, Karin Hellström et al. · Blood · 2013 · 127 citations

Medicine, Oncology, Pharmacotherapy +13

Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients

Henrik Hjorth‐Hansen, Jesper Stentoft, Johan Richter et al. · Leukemia · 2016 · 72 citations

Medicine, Oncology, Pharmacology +10

Second malignancies following treatment of chronic myeloid leukaemia in the tyrosine kinase inhibitor era

Niklas Gunnarsson, Leif Stenke, Martin Höglund et al. · British Journal of Haematology · 2015 · 65 citations · Full text

Medicine, Hematology, Oncology +14

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase‐2 study (<scp>N</scp>ord<scp>CML</scp>006)

Henrik Hjorth‐Hansen, Leif Stenke, Stina Söderlund et al. · European Journal Of Haematology · 2014 · 63 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +9